



The 65th ASH Annual Meeting Abstracts

ONLINE PUBLICATION ONLY

903.HEALTH SERVICES AND QUALITY IMPROVEMENT -MYELOID MALIGNANCIES

Effectiveness of Cross-Platform Online Activities to Reinforce Physician Competence Around BCMA-Directed Therapies in Multiple MyelomaElizabeth J. Heller¹, Keira P Smith², Lyn F Brook², Eden EED Maack, PhD³, Rahul Banerjee, MD⁴¹ i3 Health, Acton, MA² Oncology Data Advisor, Rochelle Park, NJ³ i3 Health, Rochelle Park, NJ⁴ Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA

Background: Multiple myeloma (MM) treatments have grown more complex in the past 5 years, with several approved treatment options targeting B-cell maturation antigen (BCMA) and emerging data around soluble BCMA and sequencing BCMA-directed therapies. Understanding these new diagnostic and treatment paradigms is important to inform rational clinical decision making in MM. Video platforms such as YouTube and VuMedi can provide a convenient and costless method to deliver content, but their ability to reach and teach US physicians has not been studied extensively for MM. We investigated usage and pre/post survey data from viewers of a continuing medical education (CME) video activity about BCMA in MM, which was available on several online platforms.

Methods: We developed a CME-approved lecture with Hematology/Oncology Fellows as a target audience. The video entitled *Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma* discussed BCMA-targeting therapies and soluble BCMA in the context of a larger framework around risk assessment and treatment decision making in MM. The 1.00-hour streaming video lecture was made accessible as a CME-approved enduring webinar archive starting on May 23, 2023, on the i3 Health website, YouTube, and VuMedi. Viewers could receive CME credit by completing assessments and evaluations on the i3 Health website, which included repeated-pairs pre- and post-activity case-based questions and self-perceived gains in confidence and competence using 5-point Likert scale questions. Responses were analyzed descriptively, with Fisher's exact test used to compare responses to questions.

Results: At the 2-month follow-up date of July 23, 2023, the video has been viewed 211 times, with 55 views on i3 Health, 139 views on YouTube, and 17 views on VuMedi, representing viewers from across the US and internationally. Baseline assessment data revealed gaps in knowledge in all areas that were addressed by the activity (Table 1). For learners who completed the assessments in the enduring activity, the mean score for all topics combined rose by 52% (37% vs 89%). The activity resulted in significant gains in knowledge and competence related to these topics, with $P < 0.001$ for all learning gains (Table 1). Upon completion of the activity, 96% of learners self-reported that knowledge acquired from this activity would be utilized to improve the outcomes of their patients, and 96% of learners self-reported that based on the information learned during the activity, they felt more confident in treating patients with MM.

Conclusion: Over 200 US viewers from both rural and urban areas have viewed this lecture, primarily on YouTube but also on other platforms. Based on viewership of i3 Health's accredited activities from the past year, more than 1,200 viewers from 30 countries are expected to be represented by the end of the 12-month period. The post-activity assessment demonstrates notable areas of knowledge gains around BCMA-directed therapies in MM. The improvements in competence seen on the case-based assessment questions, as well as gains in self-perceived competence and confidence in treating patients with cancer, show significant impact and the educational benefits of online video viewing.

Disclosures Heller: Novartis: Current equity holder in publicly-traded company; *GlaxoSmithKline:* Current equity holder in publicly-traded company. **Banerjee:** BMS: Consultancy; *Janssen:* Consultancy; *Genentech:* Consultancy; *SparkCures:* Consultancy; *Sanofi:* Consultancy; *Caribou:* Consultancy; *Pfizer:* Consultancy; *Pack Health:* Research Funding.

Table 1: Learner Competence

Case-based topic	n	Pretest correct responses (%)	Posttest correct responses (%)	Knowledge gap at baseline (%)	Learning gain (%)
Mechanism of action of BCMA-directed bispecific antibody	49	22.45	73.47	77.55	51.02 (p<.001)
Soluble BCMA (sBCMA) levels testing for prognosis and management	49	38.78	87.76	61.22	48.98 (p<.001)
MRD negativity assessment for multiple myeloma	49	32.65	87.76	67.35	55.11 (p<.001)
Sequencing of BCMA-directed therapies	49	48.98	97.96	51.02	48.98 (p<.001)
Safety of CAR-T cell therapy with ciltacabtagene autoleucel	49	24.49	95.92	75.51	71.43 (p<.001)
Safety of CAR-T cell therapy with idecabtagene vicleucel	49	55.10	91.84	44.90	36.74 (p<.001)

Figure 1

<https://doi.org/10.1182/blood-2023-181839>

Downloaded from http://ashpublications.net/blood/article-pdf/142/Supplement_1/7286/2189524/blood-3881-main.pdf by guest on 08 June 2024